Based on the above data, and considering the lack of effective therapies for 50% of TMZ-treated patients with glioma [29], we have assumed that COX-2 inhibitors and PPARγ agonists could exert amplified anti-glioma effects, since studies report such synergistic tumor-suppressing actions in other cancer types [30,31]. Here, PTGS2 is linked to central nervous system cancer.